Cart 0 Product Products (empty)
No products
To be determined Shipping
0,00 € Total
Prices are tax excluded
Product successfully added to your shopping cart
Quantity
Total
There are 0 items in your cart. There is 1 item in your cart.
Total products (tax excl.)
Total shipping (tax excl.) To be determined
Total (tax excl.)
Data sheet of WISP3 polyclonal antibody
| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human |
| Host species | Rabbit |
| Applications | ELISA,WB-Ce,IHC-P |
More info about WISP3 polyclonal antibody
| Brand: | Abnova |
| Reference: | PAB4837 |
| Product name: | WISP3 polyclonal antibody |
| Product description: | Rabbit polyclonal antibody raised against synthetic peptide of WISP3. |
| Gene id: | 8838 |
| Gene name: | WISP3 |
| Gene alias: | CCN6|LIBC|MGC125987|MGC125988|MGC125989|PPAC|PPD |
| Gene description: | WNT1 inducible signaling pathway protein 3 |
| Immunogen: | A synthetic peptide (conjugated with KLH) corresponding to internal region of human WISP3. |
| Protein accession: | WSP3_HUMAN |
| Form: | Liquid |
| Recommend dilutions: | ELISA (1:1000) Western Blot (1:50-200) Immunohistochemistry (1:50-100) The optimal working dilution should be determined by the end user. |
| Storage buffer: | In PBS (0.09% sodium azide) |
| Storage instruction: | Store at 4°C. For long term storage store at -20°C. Aliquot to avoid repeated freezing and thawing. |
| Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Product type: | Primary antibodies |
| Host species: | Rabbit |
| Antigen species / target species: | Human |
| Reactivity: | Human |
| Application image: |  |
| Application image note: | Western blot analysis of WISP3 polyclonal antibody (Cat # PAB4837) in HepG2 cell lysate (35 ug/lane). WISP3 (arrow) was detected using the purified polyclonal antibody. |
| Applications: | ELISA,WB-Ce,IHC-P |
| Shipping condition: | Dry Ice |
| Publications: | WISP3 is a novel tumor suppressor gene of inflammatory breast cancer.Kleer CG, Zhang Y, Pan Q, van Golen KL, Wu ZF, Livant D, Merajver SD. Oncogene. 2002 May 9;21(20):3172-80. |